... Pilot study evaluating the interaction between paclitaxel and protease inhibitors ... HIV Prevention Intervention for HIV-Positive Persons Releasing from Correctional ...

... al. Use of combination neonatal prophylaxis for the prevention of mother-to-child ... of protease inhibitors in pregnancy: maternal and fetal considerations. Infect Dis ...

... between long-term (>3 years) exposure to the protease inhibitor atazanavir and risk of myocardial infarction (RR, 0. ... 95% CI, 0.85 to 0.92]). 109 Protease inhibitor use but not non-NRTI use was associated ...

... in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue AIDS Patient ... no no no yes Cardiovascular disease no 17453589 Protease inhibitors and cardiovascular disease: analysis of the Los Angeles ...

... the diffusion of drug therapies that include a protease inhibitor or a non-nucleoside reverse transcriptase inhibitors and ... or HAART). 5 In December 1995, the first protease inhibitor was approved and several other protease inhibitors were ...

... L, et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral ... al. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One. 2012; ...

... 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial ( ... J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin ...

... and triple therapy regimens with the recently approved protease inhibitors telaprevir and boceprevir, which are used in combination ... alfa-2a or alfa-2b), ribavirin, and a protease inhibitor (either telaprevir or boceprevir) compared with dual therapy ...

... strategies consisting of non-nucleotide reverse transciptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse ...